Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Paclitaxel/Etoposide Co-Loaded Polymeric Nanoparticles on Tumor Size and Survival Rate in a Rat Model of Glioblastoma Publisher Pubmed



Maleki H1, 2 ; Hosseini Najafabadi MR1 ; Webster TJ3 ; Hadjighassem MR4 ; Sadroddiny E5 ; Ghanbari H1 ; Khosravani M1 ; Adabi M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
  3. 3. Chemical Engineering Department, Northeastern University, Boston, 02115, MA, United States
  4. 4. Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Pharmaceutics Published:2021


Abstract

The aim of this work is to co-load paclitaxel (PTX) and etoposide (ETP) in methoxy poly(ethylene glycol)-poly(lactic-co-glycolic acid) nanoparticles (mPEG-PLGA NPs) to overcome pharmacokinetics and physiological limitations and enhance therapeutic efficacy for treating intracranial glioblastoma. Both drugs were loaded into mPEG-PLGA NPs by a nano-precipitation method. The resultant NPs demonstrated an enhanced cytotoxic effect indicated by lower IC50 values and augmented cell apoptosis to U87 and C6 glioma cell lines compared to both free drugs. Additionally, blood compatibility assays showed that the PTX/ETP co-loaded mPEG-PLGA NPs did not induce blood hemolysis, blood clotting, or platelet aggregation. In vivo anti-glioma efficacy evaluation in rats bearing intracranial C6 glioma revealed a superior anti-glioma activity for the treatment with PTX/ETP co-loaded mPEG-PLGA NPs compared to other formulations, particularly a significantly longer median survival, 76 days compared to 36 days for free PTX and 37 days for free ETP treatment, respectively, and higher tumor regression, proved by magnetic resonance imaging (MRI). © 2021 Elsevier B.V.
Related Docs
View other Related Docs
1. Preparation of Paclitaxel and Etoposide Co-Loaded Mpeg-Plga Nanoparticles: An Investigation With Artificial Neural Network, Journal of Pharmaceutical Innovation (2021)
2. Polymeric Nanoparticles for Drug Delivery in Glioblastoma: State of the Art and Future Perspectives, Journal of Controlled Release (2022)
3. Paclitaxel/Methotrexate Co-Loaded Plga Nanoparticles in Glioblastoma Treatment: Formulation Development and in Vitro Antitumor Activity Evaluation, Life Sciences (2020)
4. Combination Chemotherapy Via Poloxamer 188 Surface-Modified Plga Nanoparticles That Traverse the Blood–Brain–Barrier in a Glioblastoma Model, Scientific Reports (2024)
5. Chitosan/Pva Nanofiber for the Application in Implantable Drug Delivery Systems, Nanomedicine Research Journal (2022)
6. A Combinational Approach Towards Treatment of Breast Cancer: An Analysis of Noscapine-Loaded Polymeric Nanoparticles and Doxorubicin, AAPS PharmSciTech (2020)
7. Polymeric Nanoparticles for Dna Vaccine-Based Cancer Immunotherapy: A Review, Biotechnology Letters (2023)
8. Preparation of Surface-Modified Plga Nanoparticles Containing Carbon Quantum Dots: Insights From C6 Cell Line Assays, Nanomedicine (2025)
Experts (# of related papers)
View all Related Experts
Mahdi Adabi (7)
Masood Khosravani (7)
Other Related Docs
9. Local Delivery of Ibrutinib by Folate Receptor-Mediated Targeting Plga–Peg Nanoparticles to Glioblastoma Multiform: In Vitro and in Vivo Studies, Journal of Drug Targeting (2025)
10. Clinical Applications of Nanomedicine in Cancer Therapy, Drug Discovery Today (2020)
11. Combination Nanochemotherapy of Brain Tumor Using Polymeric Nanoparticles Loaded With Doxorubicin and Paclitaxel: An in Vitro and in Vivo Study, European Journal of Pharmaceutics and Biopharmaceutics (2023)